In two targeted cohort studies using anti-PD1 and anti-CTLA-4 inhibitors to target non-small-cell lung cancer (NSCLC) and melanoma, positive associations between TMB and ICB responses was revealed [15, 16]. Here, PDCD1 is linked to melanoma.